Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alan W, Skolnick"'
Autor:
Fatih M Uckun, Muhammad Saeed, Mustafa Awili, Ibrahim H Ozercan, Sanjive Qazi, Cynthia Lee, Adeel Shibli, Alan W Skolnick, Alonso Prusmack, Joseph Varon, Cesar IP Barrera, Cemal Orhan, Michael Volk, Kazim Sahin
Publikováno v:
Future Microbiology. 17:1217-1229
Aim: Our main objectives were to compare the effects of Rejuveinix (RJX), dexamethasone (DEX) and their combination on the severity of sepsis and survival outcome in an animal model of fatal sepsis. Methods: We used the LPS plus D-galactosamine mouse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02e560a410019f67eca3276e8a61f85a
https://doi.org/10.2217/fmb-2022-0044
https://doi.org/10.2217/fmb-2022-0044
Autor:
Kevin L, Winthrop, Alan W, Skolnick, Adnan M, Rafiq, Scott H, Beegle, Julian, Suszanski, Guenther, Koehne, Ofra, Barnett-Griness, Aida, Bibliowicz, Reza, Fathi, Patricia, Anderson, Gilead, Raday, Gina, Eagle, Vered Katz, Ben-Yair, Harold S, Minkowitz, Mark L, Levitt, Michael S, Gordon
Publikováno v:
Open Forum Infectious Diseases. 9
Background Opaganib, an oral sphingosine kinase-2 inhibitor with antiviral and anti-inflammatory properties, was shown to inhibit severe acute respiratory syndrome coronavirus 2 replication in vitro. We thus considered that opaganib could be benefici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68f33875e2beb27da2f8d2f5e869c44f
https://doi.org/10.1093/ofid/ofac232
https://doi.org/10.1093/ofid/ofac232
Autor:
Fatih M. Uckun, Muhammad Saeed, Mustafa Awili, Ibrahim H. Ozercan, Sanjive Qazi, Cynthia Lee, Adeel Shibli, Alan W. Skolnick, Alonso Prusmack, Joseph Varon, Cesar I.P. Barrera, Cemal Orhan, Michael Volk, Kazim Sahin
BackgroundThe identification of effective strategies capable of reducing the case mortality rate of high-risk COVID-19 is an urgent and unmet medical need. We recently reported the clinical safety profile of RJX, a well-defined intravenous GMP-grade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7553271c8244ab1c0c048c0b1a12402
https://doi.org/10.1101/2022.02.12.22270748
https://doi.org/10.1101/2022.02.12.22270748
Autor:
Scott Beegle, Alan W Skolnick, Mark L. Levitt, Michael S Gordon, Patricia Anderson, Harold S Minkowitz, Gina Eagle, Guenther Koehne, Gilead Raday, Kevin L. Winthrop, Adnan Rafiq, Reza Fathi, Aida Bibliowicz, Ofra Barnett-Griness, Vered Katz Ben-Yair, Julian Suszanski
BackgroundOpaganib, an oral sphingosine kinase-2 inhibitor with antiviral and anti-inflammatory properties, was shown to inhibit SARS-CoV-2 replication in vitro. We thus considered that opaganib could be beneficial for moderate to severe COVID-19 pne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11367e9baa18250ae680554587c233e6
https://doi.org/10.1101/2021.08.23.21262464
https://doi.org/10.1101/2021.08.23.21262464